BIOLASE, Inc. (NASDAQ: BIOL) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
BIOLASE, Inc. (NASDAQ: BIOL) had its "speculative buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $0.40 price target on the stock.
BIOLASE Voluntarily Initiates Chapter 11 Proceedings
BIOLASE, Inc. (NASDAQ: BIOL) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
BIOLASE, Inc. (NASDAQ: BIOL) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.